PET/CT detects colorectal cancer recurrences
PET/CT scans can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment, according to a study presented at the ARRS annual meeting.
PET/CT scans can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment, according to a study presented at the ARRS annual meeting.
Researchers at The Christie NHS Foundation Trust in Manchester, U.K., found 71 patients with suspected co-lorectal recurrence. Suspicion was based on CT and MR in 51 cases. The rest had a suspected recurrence based on a carcinoembryonic antigen test with unremarkable conventional imaging.
All 71 patients had a PET/CT scan to confirm or negate recurrence. The modality accurately confirmed a recurrence in 40 of 71 patients.
“This shows that PET/CT has a definite role in the management of patients with recurrent colorectal cancer in addition to conventional imaging and the CEA test,” said Dr. Rohit Kochhar, lead author of the study.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
